Pharmacyclics completes enrollment in phase III Ibrutinib CLL study pharmabiz.com ... planned 110 patients in the phase II single-arm study using ibrutinib in patients with mantle cell lymphoma (MCL) who progress after bortezomib therapy and have received at least one prior rituximab-containing chemotherapy regimen, SPARK (MCL2001). PCYC Completes RESONATE Enrollment |
